LLY
ELI LILLY & Co
NYSE · Healthcare · Drug Manufacturers - General · US
$1,414.27
+0.35%Year over year
Reported trailing growth
- Revenue
- +45.5%
- EBITDA
- +76.9%
- EBIT
- +49.7%
- EPS
- +50.6%
- Free cash flow
- +118.0%
- Operating cash flow
- +90.8%
Forward estimates
Based on analyst estimates
- Revenue
- +14.9%
- EBITDA
- +19.4%
- EPS
- +50.2%
Three-year CAGR
- Revenue
- +31.7%
- EBITDA
- +54.1%
- EBIT
- +50.8%
- Net income
- +49.0%
- EPS
- +52.0%
- Free cash flow
- +24.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026